Details of the Drug Combination

General Information of Drug Combination (ID: DC9XWDV)

Drug Combination Name
Nintedanib Nintedanib
Indication
Disease Entry Status REF
Carcinoma, Hepatocellular Phase 1 [1]
Component Drugs Nintedanib   DMMQ2OW Nintedanib   DMMQ2OW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

References

1 ClinicalTrials.gov (NCT01594125) Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
3 Nintedanib FDA Label
4 ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.